维普中文期刊产品整合服务
18篇 您的检索式:作者名="Todd Evans"
    题名 作者 年代 出处 被引量
1Horizontal well IPR calculation显示文摘THOMS L K TODD B J EVANS C E 1998SPE Reservoir Evaluation & Engineering1998,1,39:1
2Cloning and expression pattern of the Xenopus erythropoietin receptor显示文摘Donald A. Yergeau Matthew Schmerer Emin Kuliyev Todd Evans Paul E. Mead 2005Gene Expression Patterns2005,,4:1
3Development and Characterization of a Scalable Controlled Precipitation Process to Enhance the Dissolution of Poorly Water-Soluble Drugs显示文摘True L. Rogers Ian B. Gillespie James E. Hitt Kevin L. Fransen Cindy A. Crowl Christopher J. Tucker Gary B. Kupperblatt Joe N. Becker Deb L. Wilson Clifford Todd Charles F. Broomall Jonathan C. Evans Edmund J. Elder 2004Pharmaceutical Research2004,,11:1
4Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma显示文摘Kelly M. McMasters Todd M. Tuttle Steven D. Leach Tyvin Rich Karen R. Cleary Douglas B. Evans Steven A. Curley 1997The American Journal of Surgery1997,,6:1
5Optimum preparation of silanes for steel pre-treatment 显示文摘CUNLIFFE A V EVANS S TODD A 2001International Journal of Adhesion & Adhesives2001,21,:1
6Departure from Navier-Stokes hydrodynamics in confined liquids 显示文摘K P Travis B D Todd D J Evans 1997Physical Review E1997,55,4:1
7Poiseuille flow of molecular fluids显示文摘TRAVIS K P TODD B D EVANS D J 1997PhysicalA1997,240,:1
8Poiseuille Flow of Molectular Fluids 显示文摘Travis K P Todd B D Evans D J 1997Physica A1997,240,12:1
9Departure from Navier-Stokes hydrodynamics in confined liquids显示文摘Travis K P Todd B D Evans D J 1997Physical Review E1997,55,:1
10Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma显示文摘Kelly M. McMasters Todd M. Tuttle Steven D. Leach Tyvin Rich Karen R. Cleary Douglas B. Evans Steven A. Curley 1997The American Journal of Surgery1997,,6:1
11Departure fromnavier-stokes hydrodynamics in confined liquids显示文摘TRAVIS K P TODD B D EVANS D J 1997Physical Review E1997,55,4:1
12A multivariate time series approach to modeling and forecasting demand in the emergency department显示文摘Spencer S. Jones R. Scott Evans Todd L. Allen Alun Thomas Peter J. Haug Shari J. Welch Gregory L. Snow 2008Journal of Biomedical Informatics2008,,1:1
13Real-time fMRI links subjective experience with brain activity during focused attention显示文摘Kathleen A. Garrison Dustin Scheinost Patrick D. Worhunsky Hani M. Elwafi Thomas A. Thornhill Evan Thompson Clifford Saron Ga?lle Desbordes Hedy Kober Michelle Hampson Jeremy R. Gray R. Todd Constable Xenophon Papademetris Judson A. Brewer Neuroimage0,,:1
14KDR Identifies a Conserved Human and Murine Hepatic Progenitor and Instructs Early Liver Development显示文摘Orit Goldman Songyan Han Marion Sourrisseau Noelle Dziedzic Wissam Hamou Barbara Corneo Sunita D’Souza Thomas Sato Darrell N. Kotton Karl-Dimiter Bissig Tamara Kalir Adam Jacobs Todd Evans Matthew J. Evans Valerie Gouon-Evans 2013Cell Stem Cell2013,,6:1
15A targetable pathway to eliminate TRA-1-60^(+)/TRA-1-81^(+)chemoresistant cancer cells显示文摘Chemoresistance is a primary cause of treatment failure in pancreatic cancer.Identifying cell surface markers specifically expressed in chemoresistant cancer cells(CCCs)could facilitate targeted therapies to overcome chemoresistance.We performed an antibody-based screen and found that TRA-1-60 and TRA-1-81,two‘stemness’cell surface markers,are highly enriched in CCCs.Further-more,TRA-1-60^(+)/TRA-1-81^(+)cells are chemoresistant compared to TRA-1-60^(-)/TRA-1-81^(-)cells.Transcriptome profiling identified UGT1A10,shown to be both necessary and sufficient to maintain TRA-1-60/TRA-1-81 expression and chemoresistance.From a high-content chemical screen,we identified Cymarin,which downregulates UGT1A10,eliminates TRA-1-60/TRA-1-81 expression,and increases chemosensitivity both in vitro and in vivo.Finally,TRA-1-60/TRA-1-81 expression is highly specific in primary cancer tissue and positively correlated with chemoresistance and short survival,which highlights their potentiality for targeted therapy.Therefore,we discovered a novel CCC surface marker regulated by a pathway that promotes chemoresistance,as well as a leading drug candidate to target this pathway.Lei Tan Xiaohua Duan Pratyusha Mutyala Ting Zhou Sadaf Amin Tuo Zhang Brian Herbst Gokce Askan Tomer Itkin Zhaoying Xiang Fabrizio Michelassi Michael D.Lieberman Christine AIacobuzio-Donahue Steven DLeach Todd Evans Shuibing Chen 2023Journal of Molecular Cell Biology2023,15,6:0
16Modeling endodermal organ development and diseases using human pluripotent stem cell-derived organoids显示文摘Recent advances in development of protocols for directed differentiation from human pluripotent stem cells(hPSCs)to defined lineages,in combination with 3D organoid technology,have facilitated the generation of various endoderm-derived organoids for in vitro modeling of human gastrointestinal development and associated diseases.In this review,we discuss current state-ofthe-art strategies for generating hPSC-derived endodermal organoids including stomach,liver,pancreatic,small intestine,and colonic organoids.We also review the advantages of using this system to model various human diseases and evaluate the shortcomings of this technology.Finally,we emphasize how other technologies,such as genome editing and bioengineering,can be incorporated into the 3D hPSC-organoid models to generate even more robust and powerful platforms for understanding human organ development and disease modeling.Fong Cheng Pan Todd Evans Shuibing Chen 2020Journal of Molecular Cell Biology2020,12,8:0
17Comments on ‘An airway organoid-based screen identifies a role for the HIF1α‒glycolysis axis in SARS-CoV-2 infection’显示文摘Coronavirus disease 2019(COVID-19)has been an ongoing public health crisis since the end of 2019;besides vaccine development,there have been major research efforts focused on developing antiviral therapeutics.Remdesivir was the first US Food and Drug Administration(FDA)-approved antiviral drug for COVID-19.Subsequently,the FDA granted emergency use authorization(EUA)for three monoclonal antibody treatments,including sotrovimab or a combination of casirivimab and imdevimab,or bamlanivimab and etesevimab,each of which targets the coronavirus spike protein to block viral entry.Most recently,Britain granted conditional authorization for the ribonucleoside analog molnupiravir,developed by Merck as a viral replication inhibitor.The protease inhibitor PF-07321332 developed by Pfizer and boosted by ritonavir showed promising results in a phase III clinical trial,reducing the risk of hospitalization or death by 89%compared with placebo.Xiaohua Duan Hui Wang David D.Ho Robert E.Schwartz Todd Evans Shuibing Chen 2022Journal of Molecular Cell Biology2022,14,1:0
18Dual role of lipids for genome stability and pluripotency facilitates full potency of mouse embryonic stem cells显示文摘While Mek1/2 and Gsk3βinhibition('2i')supports the maintenance of murine embryonic stem cells(EsCs)in a homogenous naive state,prolonged culture in 2i results in aneuploidy and DNA hypomethylation that impairs developmental potential.Additionally,2i fails to support derivation and culture of fully potent female ESCs.Here we find that mouse ESCs cultured in 2i/LIF supplemented with lipid-rich albumin(AlbuMAx)undergo pluripotency transition yet maintain genomic stability and full potency over long-term culture.Mechanisticaily,lipids in AlbuMAx impact intracellular metabolism including nucleotide biosynthesis,lipid biogenesis,and TCA cycle intermediates,with enhanced expression of DNMT3s that prevent DNA hypomethylation.Lipids induce a formative-like pluripotent state through direct stimulation of Erk2 phosphorylation,which also alleviates X chromosome loss in female ESCs.Importantly,both male and female'all-ESc'mice can be generated from de novo derived ESCs using AlbuMAXbased media.Our findings underscore the importance of lipids to pluripotency and link nutrient cues to genome integrity in early development.Liangwen Zhong Miriam Gordillo Xingyi Wang Yiren Qin Yuanyuan Huang Alexey Soshnev Ritu Kumar Gouri Nanjangud Daylon James C.David Allis Todd Evans Bryce Carey Duancheng Wen 2023Protein & Cell2023,14,8:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费